Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVT05 versus EU-approved Simponi in methotrexate-treated rheumatoid arthritis
2022-001825-63Phase 3Terminated
- Sponsor
- Alvotech
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing AVT05 + methotrexate with EU-approved Simponi + methotrexate (2 arms). Primary endpoint: Change from baseline in DAS28-CRP at Week 16. Started Dec 2022; status: terminated.
02
Drugs
AVT05golimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2022-001825-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001825-63.